GPBAR1 and fibrosis: Another avenue would be to develop the TGR5-specific agonist INT-777 as an antifibrotic agent, removing the potential “off- target” effects of UDCA, for the treatment of cardiac fibrosis and perhaps administer this to patients with increased risk of developing fibrosis.